Customer:
Product identity: Client/Metrc ID:

IHC LLC
0103LIRVAP200_PPine

22-015309-0001


Received:

Summary

| Analyte | Result (\%) |  |  | $\left[\begin{array}{cc}--------------76 \%\end{array}\right]$ |
| :---: | :---: | :---: | :---: | :---: |
| $\Delta 8$-THC | 76.2 |  | - $\triangle 8$-THC | CBD-Total 3.76\% |
| CBD-A | 4.16 | , | - CBD-A |  |
| $\Delta 8$-THCV | 0.379 |  | - $\triangle 8$-THCV | THC-Total 0.181\% |
| CBDV-A | 0.288 |  | CBDV-A | - - - - - - - - - - - - - - - |
| CBC-A | 0.213 |  | - CbG-A | (Reported in percent of total sample) |
| CBG-A | 0.208 |  | - THC-A |  |
| THC-A | 0.206 |  | - CBT |  |
| CBT | 0.168 |  | - CbD |  |
| CBD | 0.108 |  |  |  |


| Report Number: | 22-015309/D002.R000 |
| :--- | :--- |
| Report Date: | $12 / 19 / 2022$ |
| ORELAP\#: | OR100028 |
| Purchase Order: |  |
| Received: | $12 / 14 / 2216: 35$ |


| Customer: | IHC LLC |
| :--- | :--- |
|  | 825 NW 16th Ave |
|  | Portland Oregon 97209 |
|  | United States of America (USA) |
| Product identity: | 0103 LIRVAP200_PPine |
| Client/Metrc ID: | . |
| Sample Date: | $22-015309-0001$ |
| Laboratory ID: | No HE HEM P |
| Evidence of Cooling: |  |
| Temp: | $18.1^{\circ} \mathrm{C}$ |
| Relinquished by: | Client |

Sample Results

| Potency | Method: J AOA | C 2015 | 8-6 (m | Units \% | Batch: 2210744 | Analyze: 12/16/22 | 10:39:00 P |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Analyte | As Received | Dry weigh | LOQ | Notes |  |  |  |
| CBC | < LOQ |  | 0.0675 |  |  |  | - $\triangle 8$-THC |
| CBC-A | 0.213 |  | 0.0675 |  |  |  | - $\triangle 8$-THCV |
| CBC-Total | 0.187 |  | 0.127 |  |  |  | - CBDV-A |
| CBD | 0.108 |  | 0.0675 |  |  |  | - CbC-A |
| CBD-A | 4.16 |  | 0.0675 |  |  |  | - CBG-A |
| CBD-Total | 3.76 |  | 0.127 |  |  |  | - THC-A |
| CBDV | < LOQ |  | 0.0675 |  |  |  | - CBT |
| CBDV-A | 0.288 |  | 0.0675 |  |  |  | - CBD |
| CBDV-Total | 0.250 |  | 0.126 |  |  |  |  |
| CBE | < LOQ |  | 0.0675 |  |  |  |  |
| CBG | < LOQ |  | 0.0675 |  |  |  |  |
| CBG-A | 0.208 |  | 0.0675 |  |  |  |  |
| CBG-Total | 0.183 |  | 0.126 |  |  |  |  |
| CBL | < LOQ |  | 0.0675 |  |  |  |  |
| CBL-A | < LOQ |  | 0.0675 |  |  |  |  |
| CBL-Total | <LOQ |  | 0.127 |  |  |  |  |
| CBN | < LOQ |  | 0.0675 |  |  |  |  |
| CBT | 0.168 |  | 0.0675 |  |  |  |  |
| $\triangle 10-\mathrm{THC}$ | < LOQ |  | 0.0675 |  |  |  |  |
| $\Delta 8$-THC | 76.2 |  | 0.675 |  |  |  |  |
| $\Delta 8$-THCV | 0.379 |  | 0.0675 |  |  |  |  |
| $\Delta 9$-THC | <LOQ |  | 0.0675 |  |  |  |  |
| exo-THC | < LOQ |  | 0.0675 |  |  |  |  |
| THC-A | 0.206 |  | 0.0675 |  |  |  |  |
| THC-Total | 0.181 |  | 0.127 |  |  |  |  |
| THCV | < LOQ |  | 0.0675 |  |  |  |  |
| THCV-A | <LOQ |  | 0.0675 |  |  |  |  |
| THCV-Total | < LOQ |  | 0.126 |  |  |  |  |
| Total Cannabinoids | 81.9 |  |  |  |  |  |  |

[^0]

Report Number: 22-015309/D002.R000
Report Date: 12/19/2022
ORELAP\#: OR100028
Purchase Order:
Received: 12/14/22 16:35

These test results are representative of the individual sample selected and submitted by the client.

## Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified dearee of confidence.
$\mathrm{p}=$ ISO/IEC 17025:2017 accredited method.

## Units of Measure

\% = Percentage of sample
$\% \mathrm{wt}=\mu \mathrm{g} / \mathrm{g}$ divided by 10,000

Approved Signatory


Derrick Tanner
General Manager

12423 NE Whitaker Way
Portland, OR 97230
503-254-1794


Report Number: 22-015309/D002.R000
Report Date: 12/19/2022
ORELAP\#: OR100028
Purchase Order:
Received:
12/14/22 16:35

Hemp / Cannabls Usable / Extract / Finished Products Chain of Custody Record



ticue

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  | $\frac{E}{2}$ |  |  |  | $\begin{aligned} & \frac{\pi}{2} \\ & \frac{1}{8} \\ & \frac{1}{2} \end{aligned}$ | 砉 |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | nam | Tre |  |  |  |  |  |  |  |  |  |  |  | Servit | $\begin{aligned} & \text { Wevel } \\ & \text { ( } 4+t=1) \end{aligned}$ | Cammentuerio |
| 1 VCBLIRVAP 200_PPine |  |  |  |  | \% |  |  |  |  |  |  |  |  | C |  |  |
| 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 7 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hinusich | Date | Inine | manumar: |  |  |  |  |  |  | Dive |  | nime |  | Latuse Doke |  |  |
| Kyle Farock | 12/14 | 4.00 Pr | $A \subset$ |  |  |  |  |  |  | $12-1416.35$ |  |  |  | [1) Menesl Ma: $\qquad$ <br>  <br>  $\qquad$ 181 <br>  $\qquad$ <br>  $\qquad$ $\qquad$ Trolai manay $\qquad$ |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |


 Pathers bevtexo

Report Number: 22-015309/D002.R000
Report Date: 12/19/2022
ORELAP\#: OR100028
Purchase Order:
Received:
12/14/22 16:35


| Laboratory Quality Control Results |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Laboratory Control Sample |  |  |  |  |  |  |  |  |  |  |
| Analyte | LCS | Result | Spike | Units | \%Re |  | Limits |  | Evaluation | Notes |
| CBDVA | 2 | 0.100 | 0.101 | \% | 99.2 | 80.0 | - | 120 | Acceptable |  |
| CBDV | 2 | 0.112 | 0.110 | \% | 102 | 80.0 | - | 120 | Acceptable |  |
| CBE | 2 | 0.101 | 0.106 | \% | 95.1 | 80.0 | - | 120 | Acceptable |  |
| CBDA | 1 | 0.0996 | 0.096 | \% | 104 | 90.0 | - | 110 | Acceptable |  |
| CBGA | 1 | 0.0992 | 0.097 | \% | 103 | 80.0 | - | 120 | Acceptable |  |
| CBG | 1 | 0.100 | 0.095 | \% | 105 | 80.0 | - | 120 | Acceptable |  |
| CBD | 1 | 0.0999 | 0.096 | \% | 105 | 90.0 | - | 110 | Acceptable |  |
| THCV | 2 | 0.103 | 0.105 | \% | 97.9 | 80.0 | - | 120 | Acceptable |  |
| d8THCV | 2 | 0.101 | 0.107 | \% | 94.4 | 80.0 | - | 120 | Acceptable |  |
| THCVA | 2 | 0.101 | 0.099 | \% | 102 | 80.0 | - | 120 | Acceptable |  |
| CBN | 1 | 0.102 | 0.099 | \% | 104 | 80.0 | - | 120 | Acceptable |  |
| exo-THC | 2 | 0.0984 | 0.103 | \% | 95.9 | 80.0 | - | 120 | Acceptable |  |
| d9THC | 1 | 0.0978 | 0.102 | \% | 96.0 | 90.0 | - | 110 | Acceptable |  |
| d8THC | 1 | 0.0940 | 0.100 | \% | 93.9 | 90.0 | - | 110 | Acceptable |  |
| CBL | 2 | 0.0958 | 0.100 | \% | 95.9 | 80.0 | - | 120 | Acceptable |  |
| d10THC | 1 | NA | 0.092 | \% | NA | 80.0 | - | 120 | Acceptable | Q6 |
| CBC | 2 | 0.105 | 0.109 | \% | 96.3 | 80.0 | - | 120 | Acceptable |  |
| THCA | 1 | 0.0935 | 0.096 | \% | 97.6 | 90.0 | - | 110 | Acceptable |  |
| CBCA | 2 | 0.0996 | 0.103 | \% | 96.7 | 80.0 | - | 120 | Acceptable |  |
| CBLA | 2 | 0.104 | 0.105 | \% | 98.9 | 80.0 | - | 120 | Acceptable |  |
| CBT | 2 | 0.102 | 0.109 | \% | 93.6 | 80.0 | - | 120 | Acceptable |  |
| Method Bank |  |  |  |  |  |  |  |  |  |  |
| Analyte | Result |  | LOQ |  | Units |  | Limits |  | Evaluation | Notes |
| CBDVA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBDV |  | <LOQ | 0.077 |  | \% |  | $<0.077$ |  | Acceptable |  |
| CBE |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBDA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBGA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBG |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBD |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| THCV |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| d8THCV |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| THCVA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBN |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| exo-THC |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| d9THC |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| d8THC |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBL |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| d10THC |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBC |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| THCA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBCA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBLA |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |
| CBT |  | <LOQ | 0.077 |  | \% |  | < 0.077 |  | Acceptable |  |

ND - None Detected at or above MRL
PPD - Relative Percent Differenc
QQ - Limit of Quantitation

Units of Measure:
$\%$ - Percent


Report Number: 22-015309/D002.R000
Report Date: 12/19/2022
ORELAP\#: OR100028
Purchase Order:
Received: 12/14/22 16:35


Units of Measure:


Report Date: 12/19/2022
ORELAP\#: OR100028
Purchase Order:
Received:
12/14/22 16:35


Report Number: 22-015309/D002.R000
Report Date: 12/19/2022
ORELAP\#:
OR100028
Purchase Order:
Received:
12/14/22 16:35

Explanation of QC Flag Comments:

| Code | Explanation |
| :--- | :--- |
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or \% recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| B | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |


| Customer: | IHC LLC |
| :--- | :--- |
| Product identity: | 01LIR209_PPine |
| Client/Metrc ID: | . |
| Laboratory ID: | $22-012267-0003$ |

Summary

| Analyte | Result (\%) |  |  | ------------- |
| :---: | :---: | :---: | :---: | :---: |
| CBD-A | 61.8 |  | - CbD-A | CBD-Total $54.8 \%$ |
| CBDV-A | 4.04 | , | - CBDV-A | ------------------ |
| CBG-A | 2.32 | $\sim$ | - CBG-A | THC-Total $\quad 2.02 \%$ |
| CBC-A | 2.29 |  | CBC-A | - - - - - - - - - - |
| THC-A | 2.21 |  | - thcv-a | (Reported in percent of total sample) |
| THCV-A | 0.754 |  | - CBD |  |
| CBD | 0.567 |  | - CBG |  |
| CBG | 0.159 |  | - $\triangle 9$-THC |  |
| $\Delta 9$-THC | 0.0812 |  |  |  |

Residual Solvents:

| Analyte | Result <br> $(\boldsymbol{\mu g} / \mathbf{g})$ | Limits <br> $(\boldsymbol{\mu g} / \mathbf{g})$ | Status |
| :--- | :--- | :--- | :--- |
|  | 2480 | 5000 | pass |
| Butanes (sum) | 2480 |  |  |
| n-Butane |  |  |  |

## Pesticides:

All analytes passing and less than LOQ.

## Metals:

Less than LOQ for all analytes.

| Report Number: | $22-012267 / D 004 . R 000$ |
| :--- | :--- |
| Report Date: | $10 / 18 / 2022$ |
| ORELAP\#: | OR100028 |
| Purchase Order: |  |
| Received: | $10 / 11 / 2212: 56$ |


| Customer: | IHC LLC |
| :---: | :---: |
|  | 825 NW 16th Ave |
|  | Portland Oregon 97209 |
|  | United States of America (USA) |
| Product identity: | 01LIR209_PPine |
| Client/Metrc ID: | . |
| Sample Date: |  |
| Laboratory ID: | 22-012267-0003 |
| Evidence of Cooling: | No |
| Temp: | 10.4 |
| Relinquished by: | ramos |



THE HEMP
COLLECT

Sample Results

| Potency | Method: J AOA | C 2015 | 98-6 (mod | Units \% | Batch: 2208812 | Analyze: 10/14/22 | 7:16:00 PM |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Analyte | As Received | Dry weigh | LOQ | Notes |  |  |  |
| CBC | <LOQ |  | 0.0755 |  |  |  |  |
| CBC-A | 2.29 |  | 0.0755 |  |  |  | CBG-A |
| CBC-Total | 2.01 |  | 0.142 |  |  |  | - CBC-A |
| CBD | 0.567 |  | 0.0755 |  |  |  | - thC-A |
| CBD-A | 61.8 |  | 0.755 |  |  |  | - THCV-A |
| CBD-Total | 54.8 |  | 0.738 |  |  |  | - CBD |
| CBDV | <LOQ |  | 0.0755 |  |  |  | - CBG |
| CBDV-A | 4.04 |  | 0.0755 |  |  |  | $\Delta 9$-TH |
| CBDV-Total | 3.50 |  | 0.141 |  |  |  |  |
| CBE | < LOQ |  | 0.0755 |  |  |  |  |
| CBG | 0.159 |  | 0.0755 |  |  |  |  |
| CBG-A | 2.32 |  | 0.0755 |  |  |  |  |
| CBG-Total | 2.20 |  | 0.141 |  |  |  |  |
| CBL | <LOQ |  | 0.0755 |  |  |  |  |
| CBL-A | <LOQ |  | 0.0755 |  |  |  |  |
| CBL-Total | <LOQ |  | 0.142 |  |  |  |  |
| CBN | <LOQ |  | 0.0755 |  |  |  |  |
| CBT | <LOQ |  | 0.0755 |  |  |  |  |
| $\Delta 10-\mathrm{THC}$ | <LOQ |  | 0.0755 |  |  |  |  |
| $\Delta 8$-THC | <LOQ |  | 0.0755 |  |  |  |  |
| $\Delta 8$-THCV | < LOQ |  | 0.0755 |  |  |  |  |
| $\Delta 9$-THC | 0.0812 |  | 0.0755 |  |  |  |  |
| exo-THC | < LOQ |  | 0.0755 |  |  |  |  |
| THC-A | 2.21 |  | 0.0755 |  |  |  |  |
| THC-Total | 2.02 |  | 0.142 |  |  |  |  |
| THCV | < LOQ |  | 0.0755 |  |  |  |  |
| THCV-A | 0.754 |  | 0.0755 |  |  |  |  |
| THCV-Total | 0.662 |  | 0.141 |  |  |  |  |
| Total Cannabinoids | 74.2 |  |  |  |  |  |  |

[^1]
## 12423 NE Whitaker Way <br> Portland, OR 97230 <br> 503-254-1794



Report Number:
22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#:
OR100028
Purchase Order:
Received: 10/11/22 12:56

| Solvents | Method: Residual Solvents by GC/MS ${ }^{\text {p }}$ |  |  |  |  | Units $\mu \mathrm{g} / \mathrm{g}$ Batch 2208815 |  | Analyze 10/17/22 12:33 PM |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Analyte | Result | Limits | LOQ | Status | Notes | Analyte | Result | Limits | LOQ | Status | Notes |
| 1,4-Dioxane | <LOQ | 380 | 100 | pass |  | 2-Butanol | <LOQ | 5000 |  | pass |  |
| 2-Ethoxyethanol | < LOQ | 160 | 30.0 | pass |  | 2-Methylbutane (Isopentane) | <LOQ |  | 200 |  |  |
| 2-Methylpentane | < LOQ |  | 30.0 |  |  | 2-Propanol (IPA) | <LOQ | 5000 | 200 | pass |  |
| 2,2-Dimethylbutane | < LOQ |  | 30.0 |  |  | 2,2-Dimethylpropane (neo-pentane) | <LOQ |  | 200 |  |  |
| 2,3-Dimethylbutane | < LOQ |  | 30.0 |  |  | 3-Methylpentane | <LOQ |  | 30.0 |  |  |
| Acetone | <LOQ | 5000 | 200 | pass |  | Acetonitrile | <LOQ | 410 | 100 | pass |  |
| Benzene | <LOQ | 2.00 | 1.00 | pass |  | Butanes (sum) | 2480 | 5000 | 400 | pass |  |
| Cyclohexane | <LOQ | 3880 | 200 | pass |  | Ethyl acetate | <LOQ | 5000 | 200 | pass |  |
| Ethyl benzene | < LOQ |  | 200 |  |  | Ethyl ether | <LOQ | 5000 | 200 | pass |  |
| Ethylene glycol | < LOQ | 620 | 200 | pass |  | Ethylene oxide | <LOQ | 50.0 | 20.0 | pass |  |
| Hexanes (sum) | < LOQ | 290 | 150 | pass |  | Isopropyl acetate | <LOQ | 5000 | 200 | pass |  |
| Isopropylbenzene (Cumene) | < LOQ | 70.0 | 30.0 | pass |  | m,p-Xylene | <LOQ |  | 200 |  |  |
| Methanol | < LOQ | 3000 | 200 | pass |  | Methylene chloride | < LOQ | 600 | 60.0 | pass |  |
| Methylpropane (Isobutane) | < LOQ |  | 200 |  |  | n-Butane | 2480 |  | 200 |  | E |
| n -Heptane | < LOQ | 5000 | 200 | pass |  | n -Hexane | <LOQ |  | 30.0 |  |  |
| n -Pentane | <LOQ |  | 200 |  |  | o-Xylene | <LOQ |  | 200 |  |  |
| Pentanes (sum) | < LOQ | 5000 | 600 | pass |  | Propane | <LOQ | 5000 | 200 | pass |  |
| Tetrahydrofuran | < LOQ | 720 | 100 | pass |  | Toluene | <LOQ | 890 | 100 | pass |  |
| Total Xylenes | < LOQ |  | 400 |  |  | Total Xylenes and Ethyl benzene | <LOQ | 2170 | 600 | pass |  |

[^2]12423 NE Whitaker Way
Portland, OR 97230
503-254-1794


Report Number:
Report Date:
ORELAP\#:
0/18/2022
OR100028
Purchase Order:
Received:
10/11/22 12:56

| Pesticides | Method: AOAC 2007.01 \& EN 15662 (mod) ${ }^{\text {b }}$ |  |  |  | Units mg/kg Batch 2208761 |  | Analyze 10/14/22 10:49 AM |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Analyte | Result | Limits | LOQ Status | Notes | Analyte | Result | Limits | LOQ Status | Notes |
| Abamectin* | < LOQ | 0.50 | 0.250 pass |  | Acephate ${ }^{*}$ | < LOQ | 0.40 | 0.250 pass |  |
| Acequinocyl* | <LOQ | 2.0 | 1.00 pass |  | Acetamiprid ${ }^{*}$ | < LOQ | 0.20 | 0.100 pass |  |
| Aldicarb* | <LOQ | 0.40 | 0.200 pass |  | Azoxystrobin* | < LOQ | 0.20 | 0.100 pass |  |
| Bifenazate* | <LOQ | 0.20 | 0.100 pass |  | Bifenthrin* | < LOQ | 0.20 | 0.100 pass |  |
| Boscalid ${ }^{*}$ | < LOQ | 0.40 | 0.200 pass |  | Carbaryl* | < LOQ | 0.20 | 0.100 pass |  |
| Carbofuran* | <LOQ | 0.20 | 0.100 pass |  | Chlorantraniliprole* | < LOQ | 0.20 | 0.100 pass |  |
| Chlorfenapyr* | <LOQ | 1.0 | 0.500 pass |  | Chlorpyrifos ${ }^{*}$ | < LOQ | 0.20 | 0.100 pass |  |
| Clofentezine ${ }^{*}$ | <LOQ | 0.20 | 0.100 pass |  | Cyfluthrin* | < LOQ | 1.0 | 0.500 pass |  |
| Cypermethrin* | <LOQ | 1.0 | 0.500 pass |  | Daminozide* | < LOQ | 1.0 | 0.500 pass |  |
| Diazinon ${ }^{*}$ | <LOQ | 0.20 | 0.100 pass |  | Dichlorvos* | < LOQ | 1.0 | 0.500 pass |  |
| Dimethoate* | <LOQ | 0.20 | 0.100 pass |  | Ethoprophos* | < LOQ | 0.20 | 0.100 pass |  |
| Etofenprox* | <LOQ | 0.40 | 0.200 pass |  | Etoxazole* | < LOQ | 0.20 | 0.100 pass |  |
| Fenoxycarb ${ }^{*}$ | < LOQ | 0.20 | 0.100 pass |  | Fenpyroximate* | <LOQ | 0.40 | 0.200 pass |  |
| Fipronil* | <LOQ | 0.40 | 0.200 pass |  | Flonicamid* | < LOQ | 1.0 | 0.400 pass |  |
| Fludioxonil* | <LOQ | 0.40 | 0.200 pass |  | Hexythiazox* | < LOQ | 1.0 | 0.400 pass |  |
| Imazalil* | <LOQ | 0.20 | 0.100 pass |  | Imidacloprid* | <LOQ | 0.40 | 0.200 pass |  |
| Kresoxim-methy** | <LOQ | 0.40 | 0.200 pass |  | Malathion* | <LOQ | 0.20 | 0.100 pass |  |
| Metalaxy ${ }^{*}$ | <LOQ | 0.20 | 0.100 pass |  | Methiocarb* | < LOQ | 0.20 | 0.100 pass |  |
| Methomyl* | <LOQ | 0.40 | 0.200 pass |  | MGK-264* | <LOQ | 0.20 | 0.100 pass |  |
| Myclobutani* ${ }^{\text {* }}$ | <LOQ | 0.20 | 0.100 pass |  | Naled ${ }^{\text {F }}$ | <LOQ | 0.50 | 0.250 pass |  |
| Oxamyl* | <LOQ | 1.0 | 0.500 pass |  | Paclobutrazole* | <LOQ | 0.40 | 0.200 pass |  |
| Parathion-Methyl* | <LOQ | 0.20 | 0.200 pass |  | Permethrin* | <LOQ | 0.20 | 0.100 pass |  |
| Phosmet* | <LOQ | 0.20 | 0.100 pass |  | Piperonyl butoxide ${ }^{*}$ | <LOQ | 2.0 | 1.00 pass |  |
| Prallethrin* | <LOQ | 0.20 | 0.200 pass |  | Propiconazole ${ }^{*}$ | <LOQ | 0.40 | 0.200 pass |  |
| Propoxur* | <LOQ | 0.20 | 0.100 pass |  | Pyrethrin I (total)* | < LOQ | 1.0 | 0.500 pass |  |
| Pyridaben* | <LOQ | 0.20 | 0.100 pass |  | Spinosad* | < LOQ | 0.20 | 0.100 pass |  |
| Spiromesifen* | <LOQ | 0.20 | 0.100 pass |  | Spirotetramat ${ }^{*}$ | <LOQ | 0.20 | 0.100 pass |  |
| Spiroxamine* | <LOQ | 0.40 | 0.200 pass |  | Tebuconazole* | < LOQ | 0.40 | 0.200 pass |  |
| Thiacloprid* | <LOQ | 0.20 | 0.100 pass |  | Thiamethoxam* | < LOQ | 0.20 | 0.100 pass |  |
| Trifloxystrobin* | <LOQ | 0.20 | 0.100 pass |  |  |  |  |  |  |


| Metals |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Analyte | Result | Limits | Units | LOQ | Batch | Analyzed | Method | Status | Notes |
| Arsenic | < LOQ | 0.200 | $\mathrm{mg} / \mathrm{kg}$ | 0.0820 | 2208736 | 10/13/22 | AOAC 2013.06 (mod.) ${ }^{\text {b }}$ | pass |  |
| Cadmium | < LOQ | 0.200 | $\mathrm{mg} / \mathrm{kg}$ | 0.0820 | 2208736 | 10/13/22 | AOAC 2013.06 (mod.) ${ }^{\text {b }}$ | pass |  |
| Lead | < LOQ | 0.500 | $\mathrm{mg} / \mathrm{kg}$ | 0.0820 | 2208736 | 10/13/22 | AOAC 2013.06 (mod.) ${ }^{\text {b }}$ | pass |  |
| Mercury | <LOQ | 0.100 | $\mathrm{mg} / \mathrm{kg}$ | 0.0410 | 2208736 | 10/13/22 | AOAC 2013.06 (mod.) ${ }^{\text {b }}$ | pass |  |

[^3]These test results are representative of the individual sample selected and submitted by the client.

## Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified dearee of confidence.
$\mathrm{p}=$ ISO/IEC 17025:2017 accredited method.
${ }^{*}=$ TNI accredited analyte.

## Units of Measure

$\mu \mathrm{g} / \mathrm{g}=$ Microgram per gram
$\mathrm{mg} / \mathrm{kg}=$ Milligram per kilogram $=$ parts per million (ppm)
$\%=$ Percentage of sample
$\% \mathrm{wt}=\mu \mathrm{g} / \mathrm{g}$ divided by 10,000

## Glossary of Qualifiers

E: Analyte concentration exceeds the calibration range, results are estimated.

Approved Signatory


Derrick Tanner
General Manager

| Report Date: | $10 / 18 / 2022$ |
| :--- | :--- |
| ORELAP\#: | OR100028 |



Purchase Order:
Received:

Hemp / Cannabis Usable / Extract / Finished Products Chain of Custody Record
Revisfon: 4.00 Controit CPG23 Rev 02/24/2021 it Oy/b4/3021 OREAAP CXCRY0008





## 12423 NE Whitaker Way <br> Portland, OR 97230

503-254-1794


Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received:
10/11/22 12:56

Revision: 3 Document ID. 3120
LegacyID: CFLC21WorksheetValdated 10/30/2020

| AOAC2007.1 \&EN 15662 <br> Method Bank | Units: mg/Kg |  |  |  |  | Batch ID. 2208761 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Laboratory Control Sample |  |  |  |  |  |  |  |  |
| Analyte | Blank Reult | Blank Limits | Notes | LCSReult | LCSSpke | LCS\% Re |  | s | Notes |
| Abamectin | 0.000 | $<0.250$ |  | 0.880 | 1.000 | 88.0 | 50.0 | 150 |  |
| Acephate | 0.000 | $<0.250$ |  | 0.824 | 1.000 | 82.4 | 60.0 | 120 |  |
| Acequinocyl | 0.000 | < 1.000 |  | 3.353 | 4.000 | 83.8 | 40.0 | 160 |  |
| Acetamiprid | 0.000 | $<0.100$ |  | 0.368 | 0.400 | 91.9 | 60.0 | 120 |  |
| Aldicarb | 0.000 | $<0.200$ |  | 0.717 | 0.800 | 89.7 | 60.0 | 120 |  |
| Azoxystrobin | 0.000 | $<0.100$ |  | 0.363 | 0.400 | 90.8 | 60.0 | 120 |  |
| Bifenazate | 0.000 | $<0.100$ |  | 0.362 | 0.400 | 90.6 | 60.0 | 120 |  |
| Bifenthrin | 0.000 | $<0.100$ |  | 0.350 | 0.400 | 87.5 | 50.0 | 150 |  |
| Boscalid | 0.000 | $<0.200$ |  | 0.719 | 0.800 | 89.8 | 60.0 | 120 |  |
| Carbaryl | 0.000 | $<0.100$ |  | 0.367 | 0.400 | 91.8 | 60.0 | 120 |  |
| Carbofuran | 0.000 | $<0.100$ |  | 0.371 | 0.400 | 92.7 | 60.0 | 120 |  |
| काlorantraniliprole | 0.000 | $<0.100$ |  | 0.350 | 0.400 | 87.4 | 60.0 | 120 |  |
| कhlorfenapyr | 0.000 | < 0.500 |  | 1.607 | 2.000 | 80.3 | 60.0 | 120 |  |
| कhlorpyrifos | 0.000 | $<0.100$ |  | 0.368 | 0.400 | 92.0 | 60.0 | 120 |  |
| dofentezine | 0.000 | < 0.100 |  | 0.357 | 0.400 | 89.2 | 60.0 | 120 |  |
| Offluthrin | 0.000 | < 0.500 |  | 1.919 | 2.000 | 95.9 | 50.0 | 150 |  |
| Opermethrin | 0.000 | < 0.500 |  | 1.806 | 2.000 | 90.3 | 50.0 | 150 |  |
| Daminozide | 0.000 | < 0.500 |  | 1.886 | 2.000 | 94.3 | 60.0 | 120 |  |
| Diazinon | 0.000 | < 0.100 |  | 0.372 | 0.400 | 93.1 | 60.0 | 120 |  |
| Dichlorvos | 0.000 | < 0.500 |  | 1.842 | 2.000 | 92.1 | 60.0 | 120 |  |
| Dimethoate | 0.000 | $<0.100$ |  | 0.369 | 0.400 | 92.4 | 60.0 | 120 |  |
| Ehoprophos | 0.000 | $<0.100$ |  | 0.347 | 0.400 | 86.6 | 60.0 | 120 |  |
| Eotenprox | 0.000 | $<0.200$ |  | 0.707 | 0.800 | 88.4 | 50.0 | 150 |  |
| Eloxazle | 0.000 | $<0.100$ |  | 0.36 | 0.400 | 90.2 | 60.0 | 120 |  |
| Fenoxycarb | 0.000 | $<0.100$ |  | 0.35 | 0.400 | 88.8 | 60.0 | 120 |  |
| Fenpyroximate | 0.000 | $<0.200$ |  | 0.708 | 0.800 | 88.5 | 60.0 | 120 |  |
| Fipronil | 0.000 | < 0.200 |  | 0.719 | 0.800 | 89.9 | 60.0 | 120 |  |
| Fonicamid | 0.000 | $<0.250$ |  | 0.944 | 1.000 | 94.4 | 60.0 | 120 |  |
| Hudioxonil | 0.000 | < 0.200 |  | 0.805 | 0.800 | 100.6 | 50.0 | 150 |  |
| Hexythiazox | 0.000 | $<0.250$ |  | 0.89 | 1.000 | 89.3 | 60.0 | 120 |  |
| Imazalil | 0.000 | $<0.100$ |  | 0.371 | 0.400 | 92.6 | 60.0 | 120 |  |
| Imidacoprid | 0.000 | $<0.200$ |  | 0.72 | 0.800 | 90.8 | 60.0 | 120 |  |
| Kresoxim-methyl | 0.000 | $<0.200$ |  | 0.749 | 0.800 | 93.7 | 60.0 | 120 |  |
| Malathion | 0.000 | $<0.100$ |  | 0.364 | 0.400 | 91.0 | 60.0 | 120 |  |
| Metalaxy | 0.000 | $<0.100$ |  | 0.369 | 0.400 | 92.1 | 60.0 | 120 |  |
| Methiocarb | 0.000 | $<0.100$ |  | 0.367 | 0.400 | 91.8 | 60.0 | 120 |  |
| Methomyl | 0.000 | $<0.200$ |  | 0.666 | 0.800 | 83.2 | 60.0 | 120 |  |
| MGK264 | 0.000 | $<0.100$ |  | 0.364 | 0.400 | 91.1 | 50.0 | 150 |  |
| Mycobutanil | 0.000 | $<0.100$ |  | 0.360 | 0.400 | 90.1 | 60.0 | 120 |  |
| Naled | 0.000 | $<0.250$ |  | 0.87 | 1.000 | 87.7 | 50.0 | 150 |  |
| Oxamyl | 0.000 | < 0.500 |  | 1.911 | 2.000 | 95.5 | 60.0 | 120 |  |
| Padobutrazole | 0.000 | $<0.200$ |  | 0.715 | 0.800 | 89.4 | 60.0 | 120 |  |
| Parathion-Methyl | 0.000 | $<0.200$ |  | 0.728 | 0.800 | 91.0 | 50.0 | 150 |  |
| Permethrin | 0.000 | $<0.100$ |  | 0.35 | 0.400 | 88.8 | 50.0 | 150 |  |
| Phosmet | 0.000 | $<0.100$ |  | 0.351 | 0.400 | 87.9 | 50.0 | 150 |  |
| Pperonyl butoxide | 0.000 | $<0.500$ |  | 1.739 | 2.000 | 87.0 | 60.0 | 120 |  |
| Prallethrin | 0.000 | $<0.100$ |  | 0.368 | 0.400 | 91.9 | 60.0 | 120 |  |
| Propiconazole | 0.000 | $<0.200$ |  | 0.734 | 0.800 | 91.7 | 60.0 | 120 |  |
| Propoxur | 0.000 | $<0.100$ |  | 0.374 | 0.400 | 93.5 | 60.0 | 120 |  |
| Pyrethrin (Summe) | 0.000 | $<0.100$ |  | 0.377 | 0.413 | 91.2 | 60.0 | 120 |  |
| Pyridaben | 0.000 | $<0.100$ |  | 0.349 | 0.400 | 87.3 | 50.0 | 150 |  |
| Spinosad | 0.000 | $<0.100$ |  | 0.319 | 0.388 | 82.2 | 50.0 | 150 |  |
| Spiromesifen | 0.000 | $<0.100$ |  | 0.363 | 0.400 | 90.7 | 60.0 | 120 |  |
| Spirotetramat | 0.000 | $<0.100$ |  | 0.369 | 0.400 | 92.2 | 60.0 | 120 |  |
| Spiroxamine | 0.000 | $<0.200$ |  | 0.732 | 0.800 | 91.4 | 60.0 | 120 |  |
| Tebuconazole | 0.000 | $<0.200$ |  | 0.72 | 0.800 | 90.4 | 60.0 | 120 |  |
| Thiadoprid | 0.000 | $<0.100$ |  | 0.374 | 0.400 | 93.5 | 60.0 | 120 |  |
| Thiamethoxam | 0.000 | $<0.100$ |  | 0.359 | 0.400 | 89.8 | 60.0 | 120 |  |
| Trifloxystrobin | 0.000 | $<0.100$ |  | 0.360 | 0.400 | 89.9 | 60.0 | 120 |  |

## 12423 NE Whitaker Way <br> Portland, OR 97230

503-254-1794


Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#:
OR100028
Purchase Order:
Received:
10/11/22 12:56

Revision: 3 Document ID. 3120
LegacyID: CFLC21WorksheetValdated 10/30/2020

| AOAC2007.1 \& EN 15662 |  |  | Units: $\mathrm{mg} / \mathrm{Kg}$ |  |  |  | Batch ID 2208761 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Matrix Spke/Matri | cate Re |  |  |  |  |  | Sample ID: | 22.0121770 | 001 |  |  |
| Analyte | Result | MSRes | MSD Res | Spike | RPD\% | Limit | MS\% Re | MSD\% Re |  | mits | Notes |
| Abamectin | 0.000 | 0.638 | 0.648 | 1.000 | 1.6\% | $<30$ | 63.8\% | 64.8\% | 50 | 150 |  |
| Acephate | 0.000 | 0.605 | 0.654 | 1.000 | 7.8\% | $<30$ | 60.5\% | 65.4\% | 50 | 150 |  |
| Acequinocyl | 0.000 | 1.50 | 1.570 | 4.000 | 4.5\% | <30 | 37.5\% | 39.2\% | 50 | - 150 | Q |
| Acetamiprid | 0.000 | 0.347 | 0.354 | 0.400 | 2.0\% | <30 | 86.8\% | 88.5\% | 50 | 150 |  |
| Aldicarb | 0.000 | $0.6 \circledast$ | 0.718 | 0.800 | 7.1\% | $<30$ | 83.6\% | 89.7\% | 50 | - 150 |  |
| Azoxystrobin | 0.000 | 0.269 | 0.268 | 0.400 | 0.7\% | <30 | 67.3\% | 66.9\% | 50 | - 150 |  |
| Bifenazate | 0.000 | 0.300 | 0.319 | 0.40 | 6.2\% | $<30$ | 74.9\% | 79.7\% | 50 | 150 |  |
| Bfenthrin | 0.000 | 0.200 | 0.217 | 0.40 | 8.3\% | <30 | 49.9\% | 54.2\% | 50 | 150 | Q |
| Boscalid | $0.0 \not 09$ | 0.683 | 0.645 | 0.800 | 6.4\% | $<30$ | 76.8\% | 72.0\% | 50 | - 150 |  |
| Carbaryl | 0.000 | 0.300 | 0.297 | 0.400 | 1.1\% | $<30$ | 74.9\% | 74.1\% | 50 | 150 |  |
| Carbofuran | 0.000 | 0.278 | 0.280 | 0.40 | 0.9\% | $<30$ | 69.4\% | 70.0\% | 50 | - 150 |  |
| काlorantraniliprole | 0.000 | 0.303 | 0.312 | 0.400 | 3.0\% | $<30$ | 75.7\% | 78.0\% | 50 | 150 |  |
| कhlorfenapyr | 0.000 | 1.23 | 1.067 | 2.000 | 14.2\% | < 30 | 61.5\% | 53.4\% | 50 | 150 |  |
| कhlorpyrifos | 0.000 | 2.487 | 2.665 | 0.400 | 6.9\% | $<30$ | 6218\% | 6662\% | 50 | 150 | Q |
| dofentezine | 0.000 | 0.229 | 0.235 | 0.40 | 2.7\% | <30 | 57.1\% | 58.7\% | 50 | - 150 |  |
| Offluthrin | 0.000 | 0.871 | 0.940 | 2.000 | 7.6\% | <30 | 43.5\% | 47.0\% | 30 | - 150 |  |
| oypermethrin | 0.000 | 0.759 | 0.817 | 2.000 | 7.5\% | $<30$ | 37.9\% | 40.9\% | 50 | - 150 | Q |
| Daminozide | 0.000 | 0.290 | 0.318 | 2.000 | 9.3\% | <30 | 14.5\% | 15.9\% | 30 | - 150 | Q |
| Diażnon | 0.000 | 0.205 | 0.265 | 0.40 | 0.4\% | $<30$ | 51.3\% | 51.1\% | 50 | - 150 |  |
| Dichlorvos | 0.000 | 1.564 | 1.589 | 2.000 | 1.6\% | $<30$ | 78.2\% | 79.5\% | 50 | 150 |  |
| Dimethoate | 0.000 | 0.352 | 0.358 | 0.400 | 1.7\% | < 30 | 88.1\% | 89.6\% | 50 | - 150 |  |
| Ehoprophos | 0.000 | 0.250 | 0.250 | 0.400 | 0.2\% | $<30$ | 62.4\% | 62.5\% | 50 | - 150 |  |
| Eotenprox | 0.000 | 0.347 | 0.351 | 0.800 | 1.3\% | < 30 | 43.3\% | 43.9\% | 50 | 150 | Q |
| Eloxazle | 0.000 | 0.275 | 0.271 | 0.40 | 1.6\% | < 30 | 68.8\% | 67.7\% | 50 | - 150 |  |
| Fenoxycarb | 0.000 | 0.259 | 0.269 | 0.400 | 3.7\% | <30 | 64.\% | 67.2\% | 50 | - 150 |  |
| Fenpyroximate | 0.000 | 0.308 | 0.343 | 0.800 | 10.6\% | < 30 | 38.5\% | 42.8\% | 50 | 150 | Q |
| Fipronil | 0.000 | 0.519 | 0.550 | 0.800 | 5.7\% | $<30$ | 64.9\% | 68.7\% | 50 | - 150 |  |
| Honicamid | 0.000 | 0.92 | 0.910 | 1.000 | 1.9\% | $<30$ | 92.7\% | 91.\%\% | 50 | - 150 |  |
| Hudioxonil | 0.000 | 0.809 | 0.777 | 0.800 | 4.0\% | <30 | 101.1\% | 97.1\% | 50 | - 150 |  |
| Hexythiazox | 0.000 | 0.658 | 0.665 | 1.000 | 1.1\% | $<30$ | 65.8\% | 66.5\% | 50 | - 150 |  |
| Imazalil | 0.000 | 0.326 | 0.340 | 0.400 | 4.3\% | $<30$ | 81.5\% | 85.1\% | 50 | - 150 |  |
| Imidacoprid | 0.000 | 0.773 | 0.808 | 0.800 | 4.4\% | < 30 | 96.6\% | 101.0\% | 50 | - 150 |  |
| Kresoxim-methyl | 0.000 | 0.477 | 0.486 | 0.800 | 1.8\% | $<30$ | 59.7\% | 60.7\% | 50 | - 150 |  |
| Malathion | 0.000 | 0.236 | 0.241 | 0.40 | 2.3\% | $<30$ | 58.9\% | 60.3\% | 50 | - 150 |  |
| Metalaxy | 0.000 | 0.27 | 0.284 | 0.400 | 3.3\% | $<30$ | 68.8\% | 71.1\% | 50 | - 150 |  |
| Methiocarb | 0.000 | 0.282 | 0.281 | 0.40 | 0.6\% | $<30$ | 70.5\% | 70.1\% | 50 | - 150 |  |
| Methomyl | 0.000 | 0.748 | 0.630 | 0.800 | 17.2\% | <30 | 93.5\% | 78.7\% | 50 | - 150 |  |
| MGK264 | 0.000 | 0.154 | 0.158 | 0.40 | 2.2\% | <30 | 38.5\% | 39.4\% | 50 | - 150 | Q |
| Mycobutanil | 0.000 | 0.236 | 0.279 | 0.400 | 16.5\% | $<30$ | 59.\%\% | 69.7\% | 50 | - 150 |  |
| Naled | 0.000 | 0.634 | 0.644 | 1.000 | 1.5\% | <30 | 63.4\% | 64.4\% | 50 | - 150 |  |
| Oxamyl | 0.000 | 1.904 | 1.702 | 2.000 | 11.2\% | $<30$ | 95.2\% | 85.1\% | 50 | - 150 |  |
| Padobutrazole | 0.000 | 0.575 | $0.6 \subset 2$ | 0.800 | 4.6\% | < 30 | 71.8\% | 75.2\% | 50 | - 150 |  |
| Parathion-Methyl | 0.000 | 0.454 | 0.359 | 0.800 | 23.4\% | $<30$ | 56.7\% | 44.9\% | 30 | - 150 |  |
| Permethrin | 0.000 | 0.212 | 0.213 | 0.40 | 0.5\% | $<30$ | 53.\%\% | 53.2\% | 50 | - 150 |  |
| Phosmet | 0.000 | 0.283 | 0.293 | 0.40 | 3.4\% | <30 | 70.7\% | 73.2\% | 50 | 150 |  |
| Pperonyl butoxide | 0.000 | 1.36 | 1.377 | 2.000 | 3.8\% | < 30 | 66.2\% | 68.8\% | 50 | - 150 |  |
| Prallethrin | 0.000 | 0.197 | 0.19 | 0.40 | 1.6\% | $<30$ | 49.1\% | 48.3\% | 50 | - 150 | Q |
| Propiconazole | 0.000 | 0.62 | 0.634 | 0.800 | 2.0\% | <30 | 77.8\% | 79.3\% | 50 | - 150 |  |
| Propoxur | 0.000 | 0.297 | 0.298 | 0.40 | 0.3\% | $<30$ | 74.4\% | 74.6\% | 50 | - 150 |  |
| Pyrethrin (Summe) | 0.000 | 0.320 | 0.32 | 0.413 | 0.9\% | $<30$ | 77.5\% | 78.3\% | 50 | - 150 |  |
| Pyridaben | 0.000 | 0.26 | 0.231 | 0.40 | 2.4\% | <30 | 56.5\% | 57.9\% | 50 | - 150 |  |
| Spinosad | 0.000 | 0.230 | 0.230 | 0.388 | 0.1\% | $<30$ | 59.3\% | 59.4\% | 50 | - 150 |  |
| Spiromesifen | 0.000 | 0.267 | 0.247 | 0.400 | 7.7\% | $<30$ | 66.7\% | 61.8\% | 50 | - 150 |  |
| Spirotetramat | 0.000 | 0.506 | 0.52 | 0.400 | 3.7\% | $<30$ | 1265\% | 1313\% | 50 | - 150 |  |
| Spiroxamine | 0.000 | 0.576 | 0.62 | 0.800 | 8.2\% | $<30$ | 72.0\% | 78.2\% | 50 | - 150 |  |
| Tebuconazole | 0.000 | 0.60 | 0.649 | 0.800 | 7.7\% | $<30$ | 75.\%\% | 81.1\% | 50 | - 150 |  |
| Thiadoprid | 0.000 | 0.334 | 0.344 | 0.40 | 3.0\% | $<30$ | 83.4\% | 86.0\% | 50 | - 150 |  |
| Thiamethoxam | 0.000 | 0.358 | 0.330 | 0.400 | 8.2\% | $<30$ | 89.6\% | 82.5\% | 50 | - 150 |  |
| Trifloxystrobin | 0.000 | 0.243 | 0.247 | 0.40 | 1.5\% | <30 | 60.9\% | 61.8\% | 50 | - 150 |  |



Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received:
10/11/22 12:56

## Revision: 1 Document ID: 7148 <br> Legacy ID: Worksheet Validated 04/20/2021



ND - None Detected at or above MRL
RPD - Relative Percent Differenc
QQ - Limit of Quantitation
Units of Measure:
$\%$ - Percen

Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received: 10/11/22 12:56

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| Laboratory Quality Control Results |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| J AOAC 2015 V98-6 |  |  |  |  |  | Batch ID: 2208812 |  |  |
| Sample Duplicate |  |  |  |  |  | D: 22-012 |  |  |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes |
| CBDVA | <LOQ | <LOQ | 0.0077 | \% | NA | < 20 | Acceptable |  |
| CBDV | 0.275 | 0.274 | 0.0077 | \% | 0.216 | < 20 | Acceptable |  |
| CBE | 1.82 | 1.90 | 0.0077 | \% | 4.24 | <20 | Acceptable |  |
| CBDA | 0.934 | 0.945 | 0.0077 | \% | 1.18 | < 20 | Acceptable |  |
| CBGA | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| CBG | 1.24 | 1.21 | 0.0077 | \% | 2.28 | < 20 | Acceptable |  |
| CBD | 60.6 | 60.2 | 0.0077 | \% | 0.683 | <20 | Acceptable |  |
| THCV | <LOQ | <LOQ | 0.0077 | \% | NA | < 20 | Acceptable |  |
| d8THCV | <LOQ | <LOQ | 0.0077 | \% | NA | < 20 | Acceptable |  |
| THCVA | <LOQ | <LOQ | 0.0077 | \% | NA | < 20 | Acceptable |  |
| CBN | 1.52 | 1.53 | 0.0077 | \% | 0.203 | <20 | Acceptable |  |
| exo-THC | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| d9THC | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| d8THC | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| CBL | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| d10THC | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| CBC | 1.99 | 1.96 | 0.0077 | \% | 1.49 | <20 | Acceptable |  |
| THCA | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| CBCA | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| CBLA | <LOQ | <LOQ | 0.0077 | \% | NA | <20 | Acceptable |  |
| CBT | 1.08 | 1.14 | 0.0077 | \% | 5.43 | <20 | Acceptable |  |

ND - None Detected at or above MRL
RPD - Relative Percent Differenc
OQ - Limit of Quantitation

Units of Measure:

Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received:
10/11/22 12:56

| Laboratory Quality Control Results |  |  |  |  |  |  |  | Revision: 2 Document ID: 7087 Legacy ID: CFL-E33Effective: |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Residual Solvents |  |  |  |  |  | Batch ID: |  | 2208815 |  |  |  |
| Method Blank | Result |  |  |  | Laboratory Control Sample |  |  | \% Rec | Limits |  |  |
| Analyte |  |  | LOQ | Notes | Result | Spike | Units |  |  |  |  |
| Propane | ND | < | 200 |  | 641 | 572 | $\mu \mathrm{g} / \mathrm{g}$ | 112.160 |  | - 120 | Notes |
| Isobutane | ND | < | 200 |  | 870 | 731 | $\mu \mathrm{g} / \mathrm{g}$ | 119.0 | 60 | 120 |  |
| Butane | ND | < | 200 |  | 849 | 731 | $\mu \mathrm{g} / \mathrm{g}$ | 116.1 | 60 | 120 |  |
| 2,2-Dimethylpropane | ND | < | 200 |  | 1190 | 936 | $\mu \mathrm{g} / \mathrm{g}$ | 127.1 | 60 | - 120 | Q1 |
| Methanol | ND | < | 200 |  | 1650 | 1650 | $\mu \mathrm{g} / \mathrm{g}$ | 100.0 | 60 | - 120 |  |
| Ethylene Oxide | ND | < | 30 |  | 62.4 | 56.2 | $\mu \mathrm{g} / \mathrm{g}$ | 111.0 | 60 | - 120 |  |
| 2-Methylbutane | ND | < | 200 |  | 1580 | 1650 | $\mu \mathrm{g} / \mathrm{g}$ | 95.8 | 60 | - 120 |  |
| Pentane | ND | < | 200 |  | 1600 | 1650 | $\mu \mathrm{g} / \mathrm{g}$ | 97.06 | 60 | - 120 |  |
| Ethanol | ND | < | 200 |  | 1720 | 1660 | $\mu \mathrm{g} / \mathrm{g}$ | 103.6 | 70 | - 130 |  |
| Ethyl Ether | ND | < | 200 |  | 1640 | 1630 | $\mu \mathrm{g} / \mathrm{g}$ | 100.6 | 60 | - 120 |  |
| 2,2-Dimethylbutane | ND | < | 30 |  | 180 | 189 | $\mu \mathrm{g} / \mathrm{g}$ | 95.2 | 60 | - 120 |  |
| Acetone | ND | < | 200 |  | 1630 | 1650 | $\mu \mathrm{g} / \mathrm{g}$ | 98.8 | 60 | - 120 |  |
| 2-Propanol | ND | < | 200 |  | 1880 | 1650 | $\mu \mathrm{g} / \mathrm{g}$ | 113.9 | 60 | - 120 |  |
| Ethyl Formate | ND | < | 500 |  | 1550 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 96.3 | 70 | - 130 |  |
| Acetonitrile | ND | < | 100 |  | 576 | 504 | $\mu \mathrm{g} / \mathrm{g}$ | 114.3 | 60 | 120 |  |
| Methyl Acetate | ND | < | 500 |  | 1850 | 1630 | $\mu \mathrm{g} / \mathrm{g}$ | 113.5 | 70 | 130 |  |
| 2,3-Dimethylbutane | ND | < | 30 |  | 170 | 174 | $\mu \mathrm{g} / \mathrm{g}$ | 97.7 | 60 | - 120 |  |
| Dichloromethane | ND | < | 60 |  | 521 | 521 | $\mu \mathrm{g} / \mathrm{g}$ | 100.0 | 60 | - 120 |  |
| 2-Methylpentane | ND | < | 30 |  | 189 | 187 | $\mu \mathrm{g} / \mathrm{g}$ | 101.1 | 60 | -120 |  |
| MTBE | ND | < | 500 |  | 1770 | 1600 | $\mu \mathrm{g} / \mathrm{g}$ | 110.6 | 70 | - 130 |  |
| 3-Methylpentane | ND | $<$ | 30 |  | 191 | 188 | $\mu \mathrm{g} / \mathrm{g}$ | 101.6 | 60 | - 120 |  |
| Hexane | ND | $<$ | 30 |  | 193 | 182 | $\mu \mathrm{g} / \mathrm{g}$ | 106.0 | 60 | - 120 |  |
| 1-Propanol | ND | < | 500 |  | 1740 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 108.1 | 70 | - 130 |  |
| Methylethylketone | ND | < | 500 |  | 1810 | 1600 | $\mu \mathrm{g} / \mathrm{g}$ | 113.1 | 70 | - 130 |  |
| Ethyl acetate | ND | < | 200 |  | 1800 | 1630 | $\mu \mathrm{g} / \mathrm{g}$ | 110.4 | 60 | - 120 |  |
| 2-Butanol | ND | < | 200 |  | 1830 | 1630 | $\mu \mathrm{g} / \mathrm{g}$ | 112.3 | 60 | - 120 |  |
| Tetrahydrofuran | ND | < | 100 |  | 528 | 506 | $\mu \mathrm{g} / \mathrm{g}$ | 104.3 | 60 | - 120 |  |
| Cyclohexane | ND | < | 200 |  | 1720 | 1640 | $\mu \mathrm{g} / \mathrm{g}$ | 104.9 | 60 | - 120 |  |
| 2-methyl-1-propanol | ND | < | 500 |  | 1720 | 1620 | $\mu \mathrm{g} / \mathrm{g}$ | 106.2 | 70 | - 130 |  |
| Benzene | ND | < | 1 |  | 5.11 | 4.93 | $\mu \mathrm{g} / \mathrm{g}$ | 103.7 | 60 | - 120 |  |
| \|sopropyl Acetate | ND | < | 200 |  | 1830 | 1640 | $\mu \mathrm{g} / \mathrm{g}$ | 111.6 | 60 | - 120 |  |
| Heptane | ND | < | 200 |  | 1640 | 1630 | $\mu \mathrm{g} / \mathrm{g}$ | 100.6 | 60 | - 120 |  |
| 1-Butanol | ND | < | 500 |  | 1670 | 1600 | $\mu \mathrm{g} / \mathrm{g}$ | 104.4 | 70 | - 130 |  |
| Propyl Acetate | ND | < | 500 |  | 1820 | 1620 | $\mu \mathrm{g} / \mathrm{g}$ | 112.3 | 70 | - 130 |  |
| 1,4-Dioxane | ND | < | 100 |  | 520 | 493 | $\mu \mathrm{g} / \mathrm{g}$ | 105.5 | 60 | - 120 |  |
| 2-Ethoxyethanol | ND | < | 30 |  | 183 | 171 | $\mu \mathrm{g} / \mathrm{g}$ | 107.0 | 60 | - 120 |  |
| Methylisobutylketone | ND | < | 500 |  | 1700 | 1620 | $\mu \mathrm{g} / \mathrm{g}$ | 104.9 | 70 | - 130 |  |
| 3-Methyl-1-butanol | ND | < | 500 |  | 1690 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 105.0 | 70 | - 130 |  |
| Ethylene Glycol | ND | < | 200 |  | 459 | 494 | $\mu \mathrm{g} / \mathrm{g}$ | 92.9 | 60 | - 120 |  |
| Toluene | ND | < | 100 |  | 517 | 506 | $\mu \mathrm{g} / \mathrm{g}$ | 102.2 | 60 | - 120 |  |
| \|sobutyl Acetate | ND | < | 500 |  | 1700 | 1620 | $\mu \mathrm{g} / \mathrm{g}$ | 104.9 | 70 | - 130 |  |
| 1-Pentanol | ND | < | 500 |  | 1550 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 96.3 | 70 | - 130 |  |
| Butyl Acetate | ND | < | 500 |  | 1600 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 99.4 | 70 | - 130 |  |
| Ethylbenzene | ND | < | 200 |  | 1030 | 996 | $\mu \mathrm{g} / \mathrm{g}$ | 103.4 | 60 | - 120 |  |
| m,p-Xylene | ND | $<$ | 200 |  | 1050 | 1010 | $\mu \mathrm{g} / \mathrm{g}$ | 104.0 | 60 | - 120 |  |
| o-Xylene | ND | < | 200 |  | 989 | 979 | $\mu \mathrm{g} / \mathrm{g}$ | 101.0 | 60 | - 120 |  |
| Cumene | ND | < | 30 |  | 186 | 188 | $\mu \mathrm{g} / \mathrm{g}$ | 98.9 | 60 | - 120 |  |
| Anisole | ND | < | 500 |  | 1560 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 96.97 | 70 | - 130 |  |
| DMSO | ND | < | 500 |  | 1490 | 1600 | $\mu \mathrm{g} / \mathrm{g}$ | 93.1 | 70 | - 130 |  |
| 1,2-dimethoxyethane | ND | < | 50 |  | 207 | 190 | $\mu \mathrm{g} / \mathrm{g}$ | 108.9 | 70 | - 130 |  |
| Triethylamine | ND | < | 500 |  | 1660 | 1610 | $\mu \mathrm{g} / \mathrm{g}$ | 103.1 | 70 | - 130 |  |
| N,N-dimethylformamide | ND | < | 150 |  | 459 | 496 | $\mu \mathrm{g} / \mathrm{g}$ | 92.5 | 70 | - 130 |  |
| $\mathrm{N}, \mathrm{N}$-dimethylacetamide | ND | < | 150 |  | 477 | 483 | $\mu \mathrm{g} / \mathrm{g}$ | 98.8 | 70 | - 130 |  |
| Pyridine | ND | < | 50 |  | 163 | 167 | $\mu \mathrm{g} / \mathrm{g}$ | 97.6 | 70 | - 130 |  |
| Sulfolane | ND | < | 50 |  | 140 | 161 | $\mu \mathrm{g} / \mathrm{g}$ | 87.0 | 70 | - 130 |  |
| 1,2-Dichloroethane | ND | $<$ | 1 |  | 1.16 | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 116.0 | 70 | - 130 |  |
| Chloroform | ND | < | 1 |  | 1.17 | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 117.0 | 70 | - 130 |  |
| Trichloroethylene | ND | < | 1 |  | 1.17 | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 117.0 | 70 | - 130 |  |
| 1,1-Dichloroethane | ND | < | 1 |  | 1.14 |  | $\mu \mathrm{g} / \mathrm{g}$ | 114.0 | 70 | 130 |  |

Page 11 of 14

[^4]

Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received:
10/11/22 12:56

| QC - Sample Duplicate |  |  |  |  |  |  | $\begin{array}{r} \text { Revis } \\ \text { Leg } \\ -\mathbf{0 1 1 9 5 7 - 0 0 0} \end{array}$ | ent ID: 7087 E33Effective: |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Accept/Fail | Notes |
| Propane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | < 20 | Acceptable |  |
| Isobutane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Butane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 2,2-Dimethylpropane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | < 20 | Acceptable |  |
| Methanol | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Ethylene Oxide | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | < 20 | Acceptable |  |
| 2-Methylbutane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Pentane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | < 20 | Acceptable |  |
| Ethanol | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Ethyl Ether | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 2,2-Dimethylbutane | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Acetone | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 2-Propanol | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Ethyl Formate | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Acetonitrile | ND | ND | 100 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Methyl Acetate | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 2,3-Dimethylbutane | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Dichloromethane | ND | ND | 60 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 2-Methylpentane | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| MTBE | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 3-Methylpentane | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Hexane | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | < 20 | Acceptable |  |
| 1-Propanol | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Methylethylketone | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Ethyl acetate | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 2-Butanol | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Tetrahydrofuran | ND | ND | 100 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Cyclohexane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 2-methyl-1-propanol | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Benzene | ND | ND | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Isopropyl Acetate | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Heptane | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 1-Butanol | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Propyl Acetate | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 1,4-Dioxane | ND | ND | 100 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 2-Ethoxyethanol | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Methylisobutylketone | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 3-Methyl-1-butanol | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Ethylene Glycol | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Toluene | ND | ND | 100 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Isobuty Acetate | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 1-Pentanol | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Butyl Acetate | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Ethylbenzene | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| m,p-Xylene | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| o-Xylene | ND | ND | 200 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Cumene | ND | ND | 30 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Anisole | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| DMSO | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 1,2-dimethoxyethane | ND | ND | 50 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Triethylamine | ND | ND | 500 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| N,N-dimethylformamide | ND | ND | 150 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| N,N-dimethylacetamide | ND | ND | 150 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Pyridine | ND | ND | 50 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Sulfolane | ND | ND | 50 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| 1,2-Dichloroethane | ND | ND | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Chloroform | ND | ND | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | $<20$ | Acceptable |  |
| Trichloroethylene | ND | ND | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| 1,1-Dichloroethane | ND | ND | 1 | $\mu \mathrm{g} / \mathrm{g}$ | 0.0 | <20 | Acceptable |  |
| Abbreviations | ND - None Detected at or above MRL |  |  |  |  | Units of Measure: |  |  |
|  |  |  |  |  |  | g- Micr | m or ppm |  |
|  | RPD - Relative Percent Difference |  |  |  |  |  |  |  |
|  | LOQ - Limit of QuantitationQ1- Quality control result biased high. Only non-detect sa |  |  |  |  |  |  |  |
|  |  |  |  |  |  | ed. |  |  |

Page 12 of 14

[^5]Testing in accordance with: OAR 333-007-0400 OAR 333-007-0410 OAR 333-007-0430


Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received:
10/11/22 12:56

Report Number: 22-012267/D004.R000
Report Date: 10/18/2022
ORELAP\#: OR100028
Purchase Order:
Received:
10/11/22 12:56

Explanation of QC Flag Comments:

| Code | Explanation |
| :--- | :--- |
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or \% recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| B | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |

## SD230329-008 page 1 of 2

QA Testing
PharmLabs San Diego Certificate of Analysis
3421 Hancock St, Second Floor, San Diego, CA 92110| License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1| Accreditation \#85368
sample O3DTST224_AMBER_D8 Distillate


## CAN+ - Cannabinoids Analysis

Analyzed Apr 04, 2023 | Instrument HPLC-VWD | Method SOP-00
The expanded Uncertainty of the Cannabinoid analysis is approximately $¥ .806 \%$ at the $95 \%$ Confidence Level

| Analyte | $\begin{aligned} & \text { LOD } \\ & \mathrm{mg} / \mathrm{g} \end{aligned}$ | $\begin{aligned} & \mathrm{LOQ} \\ & \mathrm{mg} / \mathrm{g} \end{aligned}$ | $\begin{aligned} & \text { Result } \\ & \% \end{aligned}$ | Result mg/g |
| :---: | :---: | :---: | :---: | :---: |
| Cannabidivarin (CBDV) | 0.039 | 0.16 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | ND | ND |
| Tetrahydrocannabinol ( $\triangle 9-\mathrm{THC}$ ) | 0.003 | 0.16 | UI | UI |
| $\Delta 8$-tetrahydrocannabinol ( $\Delta 8$-THC) | 0.004 | 0.16 | 94.56 | 945.60 |
| Cannabicyclol (CBL) | 0.002 | 0.16 | ND | ND |
| Cannabichromene (CBC) | 0.002 | 0.16 | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | ND | ND |
| Total THC ( THCa ${ }^{\text {a }} 0.877+\Delta 9$ THC ) |  |  | ND | ND |
| Total THC $+\boldsymbol{\Delta 8} \mathbf{T H C}(\mathrm{THCa} * 0.877+\Delta 9 \mathrm{THC}+\boldsymbol{\Delta 8 T H C})$ |  |  | 94.56 | 945.60 |
| Total CBD ( CBDa $0.877+$ CBD $)$ |  |  | ND | ND |
| Total CBG ( CBGa* $0.877+$ CBG ) |  |  | ND | ND |
| Total Cannabinoids |  |  | 94.56 | 945.60 |

## HME - Heavy Metals Detection Analysis

| Analyte | $\begin{aligned} & \mathrm{LOD} \\ & \mathrm{ug} / \mathrm{g} \end{aligned}$ | $\begin{aligned} & \mathrm{LOQ} \\ & \mathrm{ug} / \mathrm{g} \end{aligned}$ | Result ug/g | $\begin{gathered} \text { Limit } \\ \text { ug/g } \end{gathered}$ | Analyte | $\begin{aligned} & \mathrm{LOD} \\ & \mathrm{ug} / \mathrm{g} \end{aligned}$ | $\begin{aligned} & \mathrm{LOQ} \\ & \mathrm{ug} / \mathrm{g} \end{aligned}$ | $\begin{aligned} & \text { Result } \\ & \mathrm{ug} / \mathrm{g} \end{aligned}$ | $\begin{aligned} & \text { Limit } \\ & \mathrm{ug} / \mathrm{g} \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Arsenic (As) | 0.0002 | 0.0005 | ND | 0.2 | Cadmium (Cd) | 3.0e-05 | 0.0005 | ND | 0.2 |
| Mercury ( Hg ) | 1.0e-05 | 0.0001 | ND | 0.1 | Lead (Pb) | $1.0 \mathrm{e}-05$ | 0.00125 | ND | 0.5 |

MIBIG - Microbial Testing Analysis

| Analyte | $\begin{aligned} & \text { Result } \\ & \mathrm{CFU} / \mathrm{g} \end{aligned}$ | Limit | Analyte | $\begin{aligned} & \text { Result } \\ & \text { CFU/g } \end{aligned}$ | Limit |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Shiga toxin-producing Escherichia Coli | ND | ND per 1 gram | Salmonella spp. | ND | ND per 1 gram |
| Aspergillus fumigatus | ND | ND per 1 gram | Aspergillus flavus | ND | ND per 1 gram |
| Aspergillus niger | ND | ND per 1 gram | Aspergillus terreus | ND | ND per 1 gram |

MTO - Mycotoxin Testing Analysis

| Analyte | $\begin{aligned} & \text { LOD } \\ & \text { ug/kg } \end{aligned}$ | $\begin{aligned} & \text { LOQ } \\ & \text { ug/kg } \end{aligned}$ | Result ug/kg (ppb) | $\begin{aligned} & \text { Limit } \\ & \mathrm{ug} / \mathrm{kg} \end{aligned}$ | Analyte | $\begin{aligned} & \text { LOD } \\ & \text { ug/kg } \end{aligned}$ | $\begin{aligned} & \text { LOQ } \\ & \text { ug/kg } \end{aligned}$ | Result ug/kg (ppb) | $\begin{gathered} \text { Limit } \\ \mathrm{ug} / \mathrm{kg} \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Ochratoxin A | 5.0 | 20.0 | ND | 20 | Aflatoxin B1 | 2.5 | 5.0 | ND | - |
| Aflatoxin B2 | 2.5 | 5.0 | ND | - | Aflatoxin G1 | 2.5 | 5.0 | ND | - |
| Aflatoxin G2 | 2.5 | 5.0 | ND | - | Total Aflatoxins | 10.0 | 20.0 | ND | 20 |



Pharm/Vare cinwas


PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1


## SD230329-008 page 2 of 2

QA Testing
PES - Pesticides Screening Analysis


RES - Residual Solvents Testing Analysis
Analyzed Apr 04, 2023 | Instrument GC/FID with Headspace Analyzer | Method SOP-006


FVI - Filth \& Foreign Material Inspection Analysis
Analyzed Mar 30, 2023 | Instrument Microscope | Method SOP-010


[^6]


## Branden starr

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1



[^0]:     prior arrangements have been made.
    Testing in accordance with: OAR 333-007-0430

[^1]:    
     prior arrangements have been made.
    Testing in accordance with: OAR 333-007-0410 OAR 333-007-0430

[^2]:    
     prior arrangements have been made.
    Testing in accordance with: OAR 333-007-0400 OAR 333-007-0410 OAR 333-007-0430

[^3]:    
     prior arrangements have been made.
    Testing in accordance with: OAR 333-007-0400 OAR 333-007-0410 OAR 333-007-0430

[^4]:     prior arrangements have been made.
    Testing in accordance with: OAR 333-007-0400 OAR 333-007-0410 OAR 333-007-0430

[^5]:     prior arrangements have been made.

[^6]:    UI Not Identified
    ND Not Detected
    N/A Not Applicable
    N/A Not Applicable
    NT Not Reported
    LOD Limit of Detection
    LOQ Limit oc Q
    <LOQ Detected
    <LOQ Detected
    >LOLOL Above upper limit of linearity
    CFU/g Colony Forming Units per 1 gram

